News Sentiment

ADPT sentiment intelligence

Adaptive Biotechnologies Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 21.06 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

86/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.6% over one week, +19.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Adaptive Biotechnologies stock hits 52-week high at 22.81 USD

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 86/100 classification
One-week reaction -0.6% Price digesting
Trend fit Trend active 19.7% over four weeks
Fair value 137.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 36
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
simplywall.st 6
Investing.com 4
MT Newswires 4
TradingView 4
Market source 4
Investing.com South Africa 3
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 7
Balance sheet 2
Analyst action 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Investing.com Direct company coverage

Adaptive Biotechnologies stock hits 52-week high at 22.81 USD

Adaptive Biotechnologies (NASDAQ: ADPT) stock reached a new 52-week high of $22.81, reflecting a 108.77% increase over the past year. This surge is supported by strong revenue growth and investor confidence in the company's biotechnology focus, despite an InvestingPro analysis su

Tone
Positive 80/100
Event
Earnings
Published
15 Jul 2026 20:16
Source
Investing.com
scanx.trade Direct company coverage

Adaptive Biotechnologies to report Q2 2026 results on July 29

Adaptive Biotechnologies Corporation is scheduled to release its financial results for the second quarter of 2026 after the market closes on July 29, 2026. A conference call will follow to discuss the results, which will be accessible via webcast on the company's website. The com

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 03:39
Source
scanx.trade
Stock Titan Direct company coverage

Adaptive Biotechnologies sets July 29 results call after market close

Adaptive Biotechnologies (ADPT) announced it will report its second-quarter 2026 financial results after market close on July 29, 2026. The company will also host a webcasted conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with the audio accessible via its

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 20:07
Source
Stock Titan
GuruFocus Direct company coverage

ADPT Maintained by Morgan Stanley -- Price Target Raised to $20.

Morgan Stanley has reiterated its "Equal-Weight" rating on Adaptive Biotechnologies (ADPT) and increased its price target from $18 to $20. Despite this, GuruFocus assesses ADPT as significantly overvalued with a GF Value™ of $10.05 against a current price of $21.77, and insider a

Tone
Negative 38/100
Event
Analyst action
Published
09 Jul 2026 17:07
Source
GuruFocus
Investing.com Nigeria Direct company coverage

Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock By Investing.com

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 386,240 shares of the company's common stock for approximately $8.5 million on July 2, 2026. These sales were conducted under a pre-arranged trading plan and occurred near the stock's

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 00:39
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Form 4 Adaptive Biotechnologies Corp For: 7 July By Investing.com

This article announces the filing of a Form 4 for Adaptive Biotechnologies Corp on July 7, 2026. The content provides the headline in multiple sections, indicating that a Form 4 document has been filed for the company with the ticker ADPT, mentioning a stock price change of -3.17

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 23:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

CSO sells 386,240 Adaptive Biotechnologies (NASDAQ: ADPT) shares under plan

Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, sold 386,240 shares of common stock on July 2, 2026. These sales were executed in two blocks at weighted-average prices of $21.74 and $22.45 per share, totaling approximately $8.50 million. The transactio

Tone
Negative 37/100
Event
Market update
Published
07 Jul 2026 23:11
Source
Stock Titan
Investing.com UK Direct company coverage

Form 4 Adaptive Biotechnologies Corp For: 6 July By Investing.com

This article reports on a Form 4 filing for Adaptive Biotechnologies Corp on July 6th. It is a brief announcement indicating the availability of the filing from Investing.com. The content primarily consists of navigation, advertisements, and market data, with the core substance b

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:08
Source
Investing.com UK
TradingView Direct company coverage

Enterprise value to EBIT forward of Adaptive Biotechnologies Corp. – DUS:1HM

The article focuses on the enterprise value to EBIT forward for Adaptive Biotechnologies Corp. (DUS:1HM), listed on the Dusseldorf Stock Exchange. It provides a financial overview and market data for the company's stock.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:10
Source
TradingView
Investing.com Direct company coverage

Adaptive Biotechnologies CCO Susan Bobulsky sells $10,714 in stock

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 487 shares of the company's common stock for $10,714 on July 1, 2026, as per a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high and considered overvalued by InvestingPro.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:08
Source
Investing.com
Investing.com Direct company coverage

Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock

Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold over $2.16 million in stock across two days in July 2026, executed under a Rule 10b5-1 trading plan. Concurrently, Lo acquired shares worth approximately $661,885 through exercising stock option

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:08
Source
Investing.com
Stock Titan Direct company coverage

Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 487 shares under 10b5-1 plan

Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 487 shares of common stock at $22.00 per share, totaling $10,714. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, she still

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 23:08
Source
Stock Titan
Stock Titan Direct company coverage

Adaptive Biotechnologies (ADPT) CPO trades 95,842 shares under 10b5-1 plan

Adaptive Biotechnologies Corp's Chief People Officer, Francis Lo, executed pre-planned stock option exercises and share sales totaling 95,842 shares between July 1-2, 2026. These transactions, made under a Rule 10b5-1 trading plan adopted in September 2025, involved selling share

Tone
Negative 37/100
Event
Market update
Published
06 Jul 2026 23:08
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Adaptive Biotechnologies Corp. – DUS:1HM

This article provides financial information for Adaptive Biotechnologies Corp. (DUS:1HM) on the Dusseldorf Stock Exchange. It specifically highlights the "Price to sales forward" metric under its financials section. The content is brief and appears to be a stub or a section of a

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:08
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Adaptive Biotechnologies Corp. – HAM:1HM

This article displays the "Price to sales forward" financial metric for Adaptive Biotechnologies Corp. (HAM:1HM) as listed on the Hamburg Stock Exchange. The current market status is closed, with no trades observed. The data is provided by ICE Data Services and FactSet Research S

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 01:39
Source
TradingView
TradingView Direct company coverage

ETFs Investing in Adaptive Biotechnologies Corp. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Adaptive Biotechnologies Corp. (1HM), traded on the Frankfurt Stock Exchange. The ETFs are sorted by their market value of the Adaptive Biotechnologies Corp. shares they hold, providing details such as is

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 11:41
Source
TradingView
Finviz Direct company coverage

ADPT - Adaptive Biotechnologies Corp Earnings

This article provides a comprehensive financial overview of Adaptive Biotechnologies Corp (ADPT), detailing its stock performance, key financial metrics, and earnings information. It highlights the company's recent earnings surprise, insider and institutional ownership, and vario

Tone
Negative 33/100
Event
Earnings
Published
03 Jul 2026 10:10
Source
Finviz
Stock Titan Direct company coverage

Harlan Robins sells 116,160 ADPT shares (ADPT) per Form 144 filing

Harlan Robins, an insider at Adaptive Biotechnologies Corp (ADPT), filed a Form 144 disclosing the proposed and recent sales of 116,160 shares of Common Stock. This filing details sales on three separate occasions in the past three months, with values totaling over $1.9 million.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

ADPT (NASDAQ: ADPT) insider sold shares via 10b5-1 plan in June 2026

An insider at Adaptive Biotechnologies Corp (NASDAQ: ADPT), Susan Bobulsky, executed three 10b5-1 sales in June 2026, totaling 21,000 shares with combined proceeds of $395,500. These routine transactions were filed via Form 144 and do not indicate new material information about t

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Francis Lo plans ADPT share sales (NASDAQ: ADPT) under Form 144

Francis Lo has filed a Form 144 to report proposed dispositions of Adaptive Biotechnologies Corp (ADPT) common stock. The filing details an exercise of stock options for 179,039 shares and a grant of 20,221 Restricted Stock Units, along with two prior 10b5-1 sales totaling over $

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:41
Source
Stock Titan
Investing.com South Africa Direct company coverage

Adaptive biotechnologies CCO Sharon Benzeno sells over $3.5m in stock

Sharon Benzeno, CCO of Adaptive Biotechnologies Corp, sold over $3.5 million worth of company stock in late June through a pre-arranged trading plan. These sales followed the exercise of stock options worth approximately $885,555. The company recently reported strong Q1 2026 reve

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 08:38
Source
Investing.com South Africa
Investing.com Australia Direct company coverage

Form 4 Adaptive Biotechnologies Corp For: 30 June By Investing.com

This article reports on the filing of Form 4 for Adaptive Biotechnologies Corp for the period ending June 30. It focuses solely on this regulatory filing, indicating an insider transaction or change in ownership that companies are required to disclose. The article is very brief,

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jul 2026 08:38
Source
Investing.com Australia